About
LicensingBioLink WeeklyJob BoardNewsContact Us
Princeton, NJ — US-China Biopharma

Catalyzing US‑China
Biotech & Pharma
Partnerships

BioRich International connects leading pharmaceutical companies and biotech innovators across the US-China corridor — facilitating licensing deals, capital connections, and R&D collaboration.

Explore Our ServicesRead BioLink Weekly
0+
Chinese Clients
0+
Projects
0+
MNC Connections
0+
Years of Experience
Our Services

Comprehensive Support Across
the Deal Lifecycle

Licensing Deals

Out-licensing & in-licensing facilitation between Chinese biotechs and global pharma. 250+ clients, 400+ projects.

Learn more

Capital & Talent

We connect biopharma companies with pre-screened US venture capital and provide executive and scientific recruitment support — drawing on one of the most extensive personal networks in US-China biopharma to place the right people at the right time.

Learn more

CRO/CDMO Matching

Selecting the right contract research or manufacturing partner is one of the highest-stakes decisions in drug development. We leverage deep relationships across the China CRO/CDMO landscape — and beyond — to match clients with partners whose capabilities align with their program requirements.

Learn more

Market Research

Understanding the China biopharma market requires specialized knowledge that is difficult to source externally. Our proprietary market reports, combined with BioLink Weekly, provide the depth and currency needed to make confident strategic decisions.

Learn more
About BioRich

A Trusted Partner at the
Intersection of East and West

Founded by John Xu, MD, MBA, MS — with over 30 years of experience at Bristol Myers Squibb, Wyeth, WuXi AppTec, and CrownBio — BioRich International operates at the nexus of US and Chinese biopharma. We bridge the information, relationship, and cultural gaps that prevent high-potential deals from closing.

Our network encompasses 250+ Chinese biotech clients, direct relationships with BD&L leadership at 25+ multinational corporations, and active engagement with more than 10 US venture capital firms.

Meet our leadership
"

The biggest obstacle to deal-making is not interest or capital — it is information asymmetry. BioLink Weekly exists to close that gap.

John Xu, MD, MBA, MS

Founder & President, BioRich International

BioLink Weekly

Intelligence for US-China Biopharma Dealmakers

View all issues →
Issue 13July 7, 2026

AstraZeneca Returns to CSPC in a $1.77B siRNA Kidney Pact as Takeda Bets Up to $600M on Insilico's AI Discovery Engine

The June 30 to July 7 window was carried by two China-linked platform licenses rather than clinical-asset buyouts. AstraZeneca went back to its go-to Chinese partner CSPC Pharmaceutical (announced July 3) in a collaboration worth up to $1.77B - $30M upfront, up to $540M in development and regulatory milestones and up to $1.2B in commercial milestones - to discover siRNA therapies for two undisclosed chronic kidney-disease pathways, with extrahepatic (renal) delivery as the technical frontier. A day earlier (July 2), Takeda signed an AI drug-discovery pact with Hong Kong-based Insilico Medicine worth up to about $600M (about $60M in project-initiation and near-term payments plus later milestones and tiered royalties), with Insilico's Pharma.AI platform leading early discovery and Takeda taking worldwide rights to selected candidates. No major M&A (control transaction) was announced in-window, following a heavy late-June cluster. On the science side, the FDA approved Orca Bio's Tregzi (Orca-T) as the first precision-engineered cell therapy for allogeneic transplant (June 30) and expanded Vertex/CRISPR's Casgevy to children aged 2 and older with sickle cell disease (July 1), with Vera Therapeutics' atacicept facing a July 7 FDA decision in IgA nephropathy.

Read issue
Issue 12June 30, 2026

China's YolTech Anchors a $230M US Gene-Editing Launch as CARsgen Wins the World's First Solid-Tumor CAR-T Approval

The June 23-30 window paired one marquee China-out license with a landmark China approval. Shanghai-based YolTech Therapeutics out-licensed SERP-01 - an in vivo base-editing therapy for alpha-1 antitrypsin deficiency - to newly launched US company Serapha Bio, taking upfront cash, a minority equity stake, and more than $2B in milestone eligibility while keeping Greater China rights; Serapha debuted via a ~$230M private placement (RA Capital, RTW) and a reverse merger into Boundless Bio (June 23). Novartis added a discovery-stage oncology pact with Scorpion spinout Antares ($105M upfront, up to $1.8B; June 24). On the science side, China's NMPA approved CARsgen's satri-cel as the world's first CAR-T for a solid tumor (June 24), and the FDA approved Viridian's Lumvoa for thyroid eye disease with a class-first active-plus-chronic label (June 26), against a backdrop of three FDA decision reversals on previously rejected cell and gene therapies.

Read issue
Issue 11June 23, 2026

Antengene Hands MPM-Backed K2 a CDH6xCD3 TCE in a ~$1B China-Out Deal; Lilly and Biogen Add Bolt-Ons as the FDA Clears the First Oral Carbapenem

The June 16-23 window restarted the China-out licensing engine after two M&A-led weeks. Antengene granted MPM BioImpact-established K2 Therapeutics exclusive ex-Greater China rights to ATG-106, a preclinical CDH6xCD3 bispecific T-cell engager, for about $20M upfront and near-term plus up to $960.5M in milestones (announced June 22), with an option on a second undisclosed TCE on similar terms. Two US bolt-on acquisitions rounded out dealmaking - Eli Lilly's purchase of non-opioid pain developer 4E Therapeutics (undisclosed, June 16) and Biogen's up-to-$1B acquisition of immunology biotech RayThera (June 17). On the science side, the FDA approved Spero/GSK's Utebzi (tebipenem pivoxil), the first oral carbapenem (June 17); MoonLake reported strong Week 52 VELA data for sonelokimab in hidradenitis suppurativa (June 21); and Definium's single-dose lysergide ODT (DT120) met its Phase 3 primary endpoint in major depression (June 22).

Read issue

Ready to Explore a Partnership?

Whether you are seeking a licensing partner, an R&D collaborator, or strategic intelligence on the China market, we are ready to help.

Get in Touch